When was Deck Bio founded?

Deck Bio was founded in 2026 and raised its 1st funding round within a year of its incorporation.

Where is Deck Bio located?

Deck Bio is headquartered in Cambridge, United States.

How many employees does Deck Bio have?

As of Jun 30, 2026, the latest employee count at Deck Bio is 3.

Is Deck Bio a funded company?

Deck Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Apr 09, 2026.

When was the latest funding round of Deck Bio?

Deck Bio's latest funding was a $***** Seed round on Apr 09, 2026, with participation from 3 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.41B in funding in 2026 to date.

Where does Deck Bio rank among its competitors?

Deck Bio ranks 16th amongst 22 active competitors, of which 7 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Deck Bio, which secured $3.1M in Apr, 2026.

Who are the top competitors of Deck Bio?

Deck Bio's top competitors include CStone Pharma, Enlaza and Baoji Pharmaceutical. Among them, Deck Bio secured the most recent funding round in April, 2026.

Deck Bio - 2026 Company Profile, Funding & Competitors

Deck Bio is a seed company based in Cambridge (United States), founded in 2026. It operates as a Developer of multi-target protein therapeutics for treating solid tumor cancers. Deck Bio has raised $3.1M in funding. The company has 22 active competitors, including 7 funded and 4 that have exited. Its top competitors include companies like CStone Pharma, Enlaza and Baoji Pharmaceutical.

Company Details

Developer of multi-target protein therapeutics for treating solid tumor cancers. These engineered proteins redirect immune cells to recognize and eliminate tumor cells by binding to multiple cancer-specific peptide-MHC targets. This approach maintains therapeutic activity despite antigen loss or tumor evolution. The technology utilizes stabilized binding domains to facilitate manufacturing and clinical development. These therapies are designed to address tumor heterogeneity and improve patient responses in various cancer indications.

Website: deck.bio
Email ID: *****@deck.bio

Key Metrics

Founded Year

2026

Location

Cambridge, United States

Stage

Seed

Total Funding

$3.1M in 1 round

Latest Funding Round

Seed, Apr 09, 2026, $*****

Investors

Mission BioCapital & 2 more

Ranked

16^th among 22 active competitors

Employee Count

3 as on Jun 30, 2026

Similar Companies

CStone Pharma & 21 more

View Deck Bio's full profile

Deck Bio has raised a total funding of $3.1M over 1 round. Its latest funding round was a Seed round on Apr 09, 2026 for $*****. 3 investors participated in its latest round. Deck Bio has 3 institutional investors.

Here is the list of recent funding rounds of Deck Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 09, 2026	8922199	Seed	8033613	8842217	1533786	6799150

Access funding benchmarks and valuations. Sign up today!

View details of Deck Bio's funding rounds and investors

Deck Bio's employee count trend

Deck Bio has 3 employees as of Jun 26. Here is Deck Bio's employee count trend over the years:

Uncover Deck Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Deck Bio include CStone Pharma, Enlaza and Baoji Pharmaceutical. Here is the list of Top 10 competitors of Deck Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CStone Pharma 2016, Shanghai (China), Public	Developing and licensing novel drugs for diseases including cancer and autoimmune diseases	$410M	GIC, 6 Dimensions Capital & 14 others	59/100
2nd	Enlaza 2020, La Jolla (United States), Series A	Developer of protein therapeutics for the treatment of cancer and other serious diseases	$176M	Avalon Ventures, J P Morgan & 9 others	57/100
3rd	Baoji Pharmaceutical 2019, Baoshan (China), Public	Developer of therapeutics for multiple diseases	$100M	Oriental Fortune Capital, Haitong Securities ... & 2 others	54/100
4th	Virometix 2009, Zurich (Switzerland), Series C	Vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases (both bacterial and viral) and cancer	$29.4M	Venture Kick	50/100
5th	GlobeImmune 1995, Louisville (United States), Public	Developing Tarmogen (vaccine) product candidates to treat cancer and infectious diseases.	$132M	Celgene, Wexford Capital & 19 others	49/100
6th	Topas Therapeutics 2016, Hamburg (Germany), Series B	Developer of nanoparticle-based therapeutics for immunology disorders	$68.5M	Epidarex Capital, Boehringer Ingelheim Venture Fund ... & 7 others	44/100
7th	Luzhu Biotech 2001, Tongzhou (China), Public	Developer of human vaccines and biological drugs for multiple diseases	$72.9M	CCB International, Tigermed & 6 others	42/100
8th	Prologue Medicines 2023, Belmont (United States), Series C	Developer of therapeutic potential of viral proteins to create transformative medicines	$50M	Flagship Pioneering	38/100
9th	Amplifier TX 2022, New York City (United States), Series A	Developer of therapeutics for metabolic and cardiovascular diseases	$33.2M	Cambrian BioPharma, RA Capital Management ... & 1 others	36/100
10th	China Resources Bio-Pharmaceutic 2016, Shenzhen (China), Series B	Developer of protein and antibody drugs to treat multiple diseases	$88.5M	National Research Fund, Cowin Capital & 5 others	35/100
16th	Deck Bio 2026, Cambridge (United States), Seed	Developer of multi-target protein therapeutics for treating solid tumor cancers	$3.1M	Mission BioCapital, BrightEdge & 1 others	26/100